Williams Hematology



Definition and History
Etiology and Pathogenesis

Clonal Hemopathy


Extramedullary Hematopoiesis
Clinical Features

Age and Sex

Presenting Symptoms

Presenting Signs

Special Clinical Features
Laboratory Features

Blood Cell Counts and Morphology

Functional Abnormalities of Blood Cells

Marrow Examination

Plasma and Urine Chemical Changes
Differential Diagnosis
Transitions to and from Myelofibrosis Among Clonal Hemopathies

The Decision to Treat

Androgens and Glucocorticoids

Recombinant Human Erythropoietin






Portal-Systemic Vascular Shunt Surgery

Marrow Curettage, Collagen Synthesis Inhibitors, Vitamin D Congeners, Immunoglobulins, and Cyclosporines

Marrow Transplantation
Course and Prognosis
Chapter References

Idiopathic myelofibrosis is one of several disorders in the spectrum of clonal hemopathies, malignant diseases that originate in the clonal expansion of a single neoplastic hematopoietic stem cell. It is characterized by anemia, mild neutrophilia, thrombocytosis, and splenomegaly. Immature myeloid and erythroid precursors, teardrop-shaped erythrocytes, and large platelets are constant features of the blood film. The marrow has increased reticulin fibers, and this reactive fibroplasia is the result of cytokines released locally by the numerous abnormal megakaryocytes. The disease may be complicated by portal hypertension, as a result of a very large splenic blood flow and the loss of compliance of hepatic vessels, and by fibrohematopoietic tumors that can develop in any tissue and lead to symptoms by compression of vital structures. Treatment may include hydroxyurea for thrombocytosis and massive splenomegaly, red cell transfusions for severe anemia, local irradiation of fibrohematopoietic tumors or of the spleen, and splenectomy. Portosystemic shunt surgery may be required for gastroesophageal variceal bleeding. The disease may remain indolent for years or may progress rapidly by further deterioration in hematopoiesis, by massive splenic enlargement and its sequelae, or by transformation to acute myelogenous leukemia. Overall median survival is about five years.

Acronyms and abbreviations that appear in this chapter include: G-6-PD, glucose-6-phosphate dehydrogenase; IL, interleukin.

Idiopathic myelofibrosis is a chronic myeloproliferative disorder characterized by (1) anemia, (2) splenomegaly, (3) immature granulocytes, erythroblasts, and teardrop-shaped red cells in the blood, and (4) marrow fibrosis. The disorder was originally described by Heuck in 1879 under the title “Two Cases of Leukemia and Peculiar Blood and Bone Marrow Findings.”1 Silverstein, in his monograph, traces the history of the concepts set forth during the first half of the twentieth century to explain the pathogenesis of this disease, including its origin in the marrow, the appearance of extramedullary hemopoiesis, and the relationship of fibrosis to hematopoietic changes.2 Over 30 designations for the disease have been proposed or used, and different ones are preferred in different countries.3 Agnogenic myeloid metaplasia and, more recently, idiopathic myelofibrosis are the two most frequently used terms for the disease. Neither designation accommodates the three key phenomena of a clonal hematopoietic stem cell abnormality, a propensity to extramedullary fibrohematopoietic tumors, and the secondary intense marrow fibrosis.302
Marrow fibrosis associated with compromise of intramedullary hematopoiesis and development of ectopic foci of hemopoiesis have been induced in animals by chemicals such as lead acetate and saponin, after infection with the Rauscher rat leukemia and S37 sarcoma viruses, by high doses of estrogens, and by overexpression of thrombopoietin.2,4 These models do not replicate the pathogenesis of human disease, which is the result of a somatic mutation in an hematopoietic stem cell.
Animals injected with marrow extracts, antimarrow serum, or egg albumin have developed marrow fibrosis and splenic hematopoiesis.2 These observations, along with reports of myelofibrosis in patients with lupus erythematosus, have suggested the possibility of immunologic-mediated hyperplasia of marrow connective tissue.2 This form of myelofibrosis is different from the monoclonal stem cell disease being considered in this chapter.
Exposure to benzene5,6 and 7 or very high dose ionizing radiation8,9 has preceded the development of idiopathic myelofibrosis in a small proportion of patients with the disease. These two incitants are well-established environmental causes of clonal myeloid disorders.
The disease arises from the neoplastic transformation of a single hemopoietic stem cell, a conclusion derived from studies in women with idiopathic myelofibrosis who were also heterozygous for isotypes A and B of G-6-PD.10,11 Although the nonhemopoietic tissues of these patients expressed both isotypes, each patient had blood cells with only one G-6-PD isotype. These findings strongly imply that the blood cells of each patient arose from only one transformed stem cell. Further, chromosome studies of colonies of hemopoietic progenitor cells in idiopathic myelofibrosis have established that a clonal cytogenetic abnormality is present in erythroblasts, neutrophils, macrophages, basophils, and megakaryocytes.12 These studies have been confirmed by (1) examining X-linked restriction fragment length polymorphisms in women with idiopathic myelofibrosis with heterozygosity for the X chromosome-linked genes13,14 and (2) verifying the presence of a mutation of codon 12 of the N-RAS gene in five blood cell lineages of a patient with the disease.15,16
Myeloproliferation is usually the dominant abnormality in the granulocytic and megakaryocytic marrow lineages resulting in blood granulocytosis and thrombocytosis. Ineffective or hypoplastic hemopoiesis can be present initially or emerge as the dominant pathogenetic process later, leading to granulocytopenia and/or thrombocytopenia. Anemia is a frequent finding as a result of a combination of hypoplastic erythropoiesis, shortened red cell survival, and the effects of massive splenomegaly on the distribution of red cells in the circulation. Hemolysis can be a prominent factor in some cases.
Four of the five major types of collagen17 are present in normal marrow: type I found in bone, type III found in blood vessels, and types IV and V found in basement membranes. The fine reticulin fibers that are visible after silver impregnation of normal marrow are principally type III collagen. They do not stain with trichrome dyes. The thicker collagen fibers are principally type I collagen and stain with trichrome dyes but do not impregnate with silver. The fine fibrous network in normal marrow that is stained by silver impregnation techniques18 is increased in amount in the marrow of virtually all patients with idiopathic myelofibrosis19 (Table 95-1). The fibrous network contains collagen and can progress occasionally to include thick collagen bands that are evident with trichrome stains. Collagen types I, III, IV, and V are increased in myelofibrosis, but type III collagen is increased uniformly and preferentially.20,21,22 and 23 The latter occurrence accounts also for the increase in the plasma concentration of procollagen III amino terminal peptide, a component of collagen type III, which is cleaved during the biosynthesis of collagen.22,24 Serum prolylhydroxylase and marrow and plasma fibronectin are also increased in patients with idiopathic myelofibrosis or myelofibrosis from other causes.14,21,22


Marrow fibrosis in idiopathic myelofibrosis is most closely correlated with an increase of dysmorphic megakaryocytes in the marrow, and even densely fibrotic marrow with little residual granulopoiesis or erythropoiesis usually has numerous megakaryocytes scattered throughout the fibrotic areas.19,38
The enhanced collagen types I and III content of marrow is the result of release of fibroblast growth factors. These include platelet-derived growth factor,39,40 epidermal growth factor,41 endothelial cell growth factor,41 transforming growth factor-b42,43 and basic fibroblast growth factor,44 each of which is present in megakaryocyte a granules. Other factors, such as tumor necrosis factor-a and IL-1 a and b, which can be released from marrow cells, also can stimulate fibroblasts.45,46 Platelet factor 4, also derived from megakaryocytes, inhibits collagenase and could contribute to collagen accumulation,38 although studies showing a poor correlation between plasma platelet factor 4 concentration and marrow fibrosis have dampened enthusiasm for the role of this factor.47 The high urinary excretion of platelet-derived calmodulin, a putative fibroblast growth factor, in patients with myelofibrosis has added this compound to the array of factors that may contribute to the fibroplasia.45 The pathogenetic role of released growth factors in fibroplasia is incompletely understood. Generalizations from in vitro experiments or correlation between two variables provide only a limited perspective. For example, transforming growth factor-b can stimulate or inhibit fibroblast growth, depending on the repertoire of other growth factors in the environment.42,43
The fibroplasia in idiopathic myelofibrosis is associated with an increase in the number and size of marrow sinuses,19,48 the number of endothelial cells,49 an increase in vascular volume in the marrow,50 and an increase in blood flow through the marrow.27,51 These processes are responsible for the increase in marrow collagen types IV and V and laminin synthesized by endothelial cells in the marrow of patients with myelofibrosis.41
The fibroblastic proliferation in marrow is not an intrinsic part of the abnormal clonal expansion of hemopoiesis.52 In cases of idiopathic myelofibrosis in which G-6-PD isoenzyme studies or chromosome karyotyping establish monoclonal growth of hemopoietic cells, marrow fibroblasts contain both G-6-PD isoenzymes and do not share the clonal chromosome abnormality.53 These findings strongly imply that the fibroblasts differentiate from a primordial cell different from the hemopoietic stem cell and that their proliferation and enhanced collagen synthesis is a secondary result of the abnormal hemopoiesis.
Extramedullary hemopoiesis is consistently present in liver and spleen,54,55 and 56 where it contributes to organ enlargement. Escape of progenitor cells from marrow and their lodgment in other organs may contribute to extramedullary blood formation. Reversion of the liver and spleen to their fetal hemopoietic functions is not held to be a major factor in the extramedullary hemopoiesis, and quantitatively significant, effective hemopoiesis does not occur outside of the marrow.
Idiopathic myelofibrosis characteristically occurs after age 50.2,54,55,56,57,58,59,60 and 61 The median age at diagnosis is about 65 years,57,58 and 59 but the disease can occur from the neonatal period to the ninth decade.57,58,62,63 Its occurrence in children is usually in the first 3 years of life.63,64 and 65 In adults the disease occurs with about equal frequency in men and women,57,58,59,60 and 61 whereas in young children girls are afflicted with the disease twice as frequently as boys.63 The disease, rarely, can be familial.67,68
About one-quarter of patients are asymptomatic at the time of diagnosis, being detected by medical examination for an unrelated reason. In symptomatic patients, fatigue, weakness, shortness of breath, and palpitations are nonspecific but frequent complaints.54,55 and 56 Weight loss is common, but anorexia is less so and night sweats occur very infrequently. A dragging sensation in the left upper abdomen caused by an enlarged spleen or early satiety from encroachment of the spleen on the stomach may occur. Severe left upper quadrant or left shoulder pain can occur from splenic infarction and perisplenitis. Patients may also report unexpected bleeding. Rarely, bone pain may be prominent, especially in the lower extremities.
Hepatomegaly is detectable in two-thirds of patients, and splenomegaly is present in virtually every patient at the time of diagnosis.2,54,55,56,57,58,59,60 and 61 The spleen is mildly enlarged in one-third and massively enlarged in one-third. Muscle wasting, peripheral edema, and purpura are present infrequently. Bone tenderness may be present.
Neutrophilic dermatosis, a syndrome that closely mimics the raised and tender plaques of Sweet syndrome may develop.69,70 and 71 It can be the presenting or a significant complicating feature of myelofibrosis and can progress to bullae or pyoderma gangrenosum.69,72 The dermatopathology of neutrophilic dermatosis is different from leukemia cutis and is unrelated to infection or vasculitis. The predominant lesion is an intense polymorphonuclear neutrophilic infiltrate.
Skin infiltrates related to hematopoietic cells (leukemia cutis) are very uncommon.73
Foci of hemopoiesis are often present in adrenals, kidneys, and lymph nodes and may become clinically apparent as fibrohemopoietic tumors in the adrenal glands,74 subcapsular renal space,75 and lymph nodes.76,77 Tumors composed of hemopoietic tissue, sometimes with intense fibrosis, can develop in the bowel,78,79,80 and 81 breast,82,83 and 84 lungs,85,86 mediastinum,85 mesentery,85 skin,87,88 synovium,89 thymus,85 thyroid,90 prostate,91 or the kidney and urinary tract.92,93,94,95 and 96
Extramedullary hemopoiesis in the intracranial or intraspinal epidural space can lead to serious neurologic complications, including subdural hemorrhage,97 delirium,98,99 increased intracranial pressure,99 papilledema,100 coma,101 motor and sensory impairment,102,103,104 and 105 spinal cord compression,103 and limb paralysis.102,103 Intraspinal myelography,103,104 computed axial tomography,97,99,101,106 positron emission tomography after 52Fe infusion,98 and magnetic resonance imaging107,108 each have been used to define the location and nature of the masses.
Hemopoietic foci on serosal surfaces can produce effusions, sometimes massive, in the thorax,109 abdomen,110,111 and pericardial space.112,113,114 and 115 The effusion fluid often contains megakaryocytes, immature granulocytes, and occasionally erythroblasts.116,117 and 118 Splenectomy is sometimes followed by extramedullary hemopoietic tumors in soft tissues,119 in body cavities, or on serosal surfaces,115 perhaps as a result of an increase in circulating hematopoietic progenitors120 and the loss of the filtration function of the spleen. In rare cases, extramedullary soft tissue megakaryoblastic tumors simulate the granulocytic sarcomas of other types of myelogenous leukemia.121,122
In patients with idiopathic myelofibrosis there can be a massive increase in splenoportal blood flow and a decrease in hepatic vascular compliance or the presence of hepatic vein thrombosis, either of which can result in severe portal hypertension, ascites, esophageal and gastric varices, intraluminal gastrointestinal bleeding, and hepatic encephalopathy.123,124 and 125 Perisinusoidal fibrosis,126,127 and 128 collagen bundles in the spaces of Disse,127 perisinusoidal fibroplasia,126,127,128 and 129 and foci of hemopoietic cells127 each appear to contribute to the decreased sinusoidal compliance.
Portal vein thrombosis is a complication of idiopathic myelofibrosis and can occasionally precede the onset of the disease.130
Abnormalities of humoral immune mechanisms have been observed in up to one-half of patients with idiopathic myelofibrosis.131,132,133,134,135 and 136 The array of immune products and events reported includes anti-red-cell antibodies,135,137 antiplatelet antibodies,138,139 antinuclear antibodies,131,132,136 elevated plasma soluble IL-2 receptor,140 anti-Gal (galactosidic determinants) antibodies,141 anti-gamma-globulins,131,132,136 antiphospholipid antibodies,136,142 antitissue or organ-specific antibodies,132,135 and circulating immune complexes,136,143,144 and 145 as well as complement activation,136,146 immune complex deposition,133 interstitial immunoglobulin deposition,133 increased numbers of marrow plasmacytoid lymphocytes,133,143 and the development of amyloidosis.144,147 Occasional reports of myelofibrosis associated with lupus erythematosus,148,149,150,151 and 152 vasculitis,153 polyarteritis nodosa,136,154 scleroderma,155 and acute reversible myelofibrosis responsive to glucocorticoids156 have raised the possibility that immune mechanisms may play a role in the development of marrow fibrosis in some circumstances.
A large proportion of patients develop osteosclerosis,57,157 reflected by increased bone density on radiographic studies and also evident on marrow biopsy.158 The proximal femur and humerus, pelvis, vertebrae, ribs, and skull may be involved. The x-ray picture may mimic the bone reaction to metastatic carcinoma. Osteolytic lesions are rare159 and may reflect a granulocytic sarcoma.160 Periostitis can lead to debilitating bone pain.54,55 and 56,161
The range of values for blood cell counts at the time of diagnosis is very broad. Normocytic-normochromic anemia is present in most, but not all, patients.2,54,55,56,57,58,59 and 60,162,163,164 and 165 The mean hemoglobin concentration at diagnosis was 9.5 to 11.6 g/dl, with a range of 4 to 20 g/dl among a total of 539 patients in four studies.56,60,163,164 Anisocytosis and poikilocytosis are a constant finding, and teardrop-shaped red cells (dacrocytes) are present in all cases in sufficient number to be found in every oil-immersion field (Fig. 95-1). Nucleated red cells are present in the blood film of most patients and average 2 percent of nucleated cells, with a range of 0 to 30 percent. The percentage of reticulocytes is mildly increased but may vary widely in a given case. Anemia may be worsened by an expansion of plasma volume and a higher-than-normal proportion of the red cell volume in an enlarged spleen. Ineffective erythropoiesis can result in a decrease in red cell mass,162 and erythroid hypoplasia is present in many patients.166,167 In some patients hemolysis may be prominent, and polychromatophilia and very elevated reticulocyte counts can occur.56,60,163,164 The antiglobulin (Coombs’) test is usually negative, but red cell autoantibodies can develop and lead to immune-mediated hemolysis.56,136,137,168 Occasional patients have a positive acid hemolysis and sucrose hemolysis test, reflecting concurrent paroxysmal nocturnal hemoglobinuria.169 Acquired hemoglobin H disease, coincident with typical white cells and platelet changes of myelofibrosis, can occur170 and results in hemolysis, hypochromic-microcytic red cells, marked poikilocytosis, and hemoglobin H inclusions that stain with brilliant cresyl blue. Red cell aplasia, in association with myelofibrosis, has also been observed.165,171

FIGURE 95-1 Blood films from two patients with idiopathic myelofibrosis. (a) Characteristic teardrop poikilocytes, a nucleated red cell, and a segmented neutrophil are evident. (b) Teardrop red cells, a nucleated red cell, and a promyelocyte are present.

The total white cell count in patients with idiopathic myelofibrosis is usually elevated mildly as a result of granulocytosis.2,54,55,56,57,58,59,60 and 61 The mean total white cell count was 10 to 14 ×109/l in four large studies. The range of white cell counts was 0.4 to 237 × 109/l at the time of diagnosis.56,60,163,164 Myelocytes and promyelocytes are present in small proportions in most patients, and a low proportion of blast cells (1–2%) may be found in the blood film in many patients. The range of blood blast cells is zero to 20 percent at the time of diagnosis. Hypersegmentation, hyposegmentation (acquired Pelger-Huët anomaly), and abnormal granulation of neutrophils may be present.2,54,55 and 56 Neutrophil alkaline phosphatase scores may be elevated (25 percent of patients) or decreased (25 percent of patients).2,172 The percent of basophils may be slightly increased.164 Neutropenia is present in about 20 percent of patients at the time of diagnosis.58
The mean platelet count has ranged from 175 to 580 × 109/l, and the range of individual counts was from 15 to 3215 × 109/l.6,60,163,164 The platelet count is elevated in about 40 percent of patients.58,164 Mild to moderate thrombocytopenia is present in about one-third of patients at the time of diagnosis. Giant platelets and abnormal platelet granulation are characteristic features of this disease.
About 10 percent of patients may present with pancytopenia because of severe impairment of hematopoiesis affecting each cell lineage, coupled with sequestration in a massively enlarged spleen.2,54,55 Pancytopenia is usually associated with intense marrow fibrosis.
Increased concentrations of pluripotential,173 granulocytic,174,175 monocytic,176,177 and erythroid178 progenitor cells are present in the blood of patients as measured by clonogenic assays of blood cells in semisolid cultures. Megakaryocytes are also present in the systemic venous blood.177
The neutrophils of some patients have impaired phagocytosis, oxygen consumption, nitroblue tetrazolium reduction, and hydrogen peroxide generation, as well as decreased myeloperoxidase178,179 and glutathione reductase activities.179 Bleeding time can be prolonged out of proportion to the platelet count.180,181 Abnormalities of platelets in patients with idiopathic myelofibrosis include impaired aggregation in response to epinephrine, depletion of dense granule adenosine diphosphate content,182 decreased platelet lipoxygenase pathway activity,183 and others.184,185 The correlation of bleeding or thrombosis with platelet functional abnormalities is weak, however.184,185 The lupus anticoagulant has been present, but only rarely.141
Marrow aspiration is often unsuccessful because of the fibrosis.18,54,60 The marrow biopsy is often cellular and shows granulocytic and megakaryocytic hyperplasia.19,164 Erythroid cells may be decreased, normal, or increased in number. Hematoxylin and eosin stains of the biopsy may show slight collagen fibrosis, but this may be extreme on occasion. In some subjects, osteosclerosis is found.19,60,164 Silver stain shows an increase in reticulin fibers, and in half the patients a striking increase in reticulin fibers is present.60,164 In intensely fibrotic marrows cellularity may be decreased, but megakaryocytes usually remain evident.60,164 Giant megakaryocytes and micromegakaryocytes, abnormal nuclear lobulation, and naked megakaryocyte nuclei may be present.60,186 Granulocytes may show hyperlobulation and hypolobulation of the nucleus, acquired Pelger-Huët anomaly, nuclear blebs, and nuclear-cytoplasmic maturation asynchrony.187 Dilated marrow sinusoids are common. Intrasinusoidal, immature hemopoietic cells, and megakaryocytes are present.19,48
Chromosome abnormalities of hemopoietic cells are evident in about forty percent of the patients at the time of diagnosis.188,189,190 and 191 The most frequent findings are partial trisomy 1q, interstitial deletion of a segment of the long arm of chromosome 13, del 13 (q13q21), which bears the retinoblastoma gene,16,189,190 and 191 and del 20q. Involvement of chromosomes 5, 7, 9, 13, 20, or 21 occurs with heightened frequency. Aneuploidy, as a result of monosomy or trisomy, is common. Pseudodiploidy, manifested by partial deletions and translocations, occurs also. Patients with typical idiopathic myelofibrosis have had the Ph chromosome in their marrow cell.192 This association is rare, however. Clonal chromosomal abnormalities found in hemopoietic cells have not been found in fibroblasts.53
Fibrosis in the marrow alters the hyperintensity of T1-weighted images that normally result from the marrow fat. As fibrosis progresses, hypointensity of T1- and T2-weighted images develops. These abnormalities are similar to those that occur with marrow hemosiderosis. Histologic confirmation by marrow biopsy of MR images is important for verification. MR imaging cannot distinguish between idiopathic myelofibrosis and secondary causes of fibrosis.193,194
The serum levels of uric acid, lactic dehydrogenase, bilirubin, alkaline phosphatase, and high-density lipoprotein are frequently elevated,54,58 and those of albumin and cholesterol are frequently decreased.58,195 Hypocalcemia196 or hypercalcemia197 may occur. Plasma levels of thrombopoietin and IL-6 are elevated but do not correlate with either platelet or megakaryocyte mass.198 Urinary excretion of calmodulin is about three times normal.45
Chronic myelogenous leukemia (see Chap. 94) should be considered in the differential diagnosis of idiopathic myelofibrosis. In chronic myelogenous leukemia the white cell count is over 30 × 109/l (30,000/µl) in virtually all patients and over 100 × 109/liter (100,000/µl) in half the patients, but in myelofibrosis it is usually less than 30 × 109/l (30,000/µl) at the time of diagnosis. In chronic myelogenous leukemia red cell shape is usually normal or slightly perturbed, whereas in myelofibrosis teardrop poikilocytes are present in every oil-immersion field and exaggerated anisocytosis and anisochromia are often prominent. The marrow in chronic myelogenous leukemia shows intense granulocytic hyperplasia with virtually 100 percent cellularity and usually no or very slight fibrosis.199 In myelofibrosis, the marrow has mildly increased cellularity or is hypocellular, with moderate to marked fibrosis. The Ph chromosome or the BCR-ABL fusion gene is present in chronic myelogenous leukemia and absent in idiopathic myelofibrosis. Rarely, patients with chronic myelogenous leukemia may develop intense marrow fibrosis and dysmorphic blood cell changes that make distinction between the two diseases difficult.199 Most cases are readily separable on the basis of the aforementioned distinctions.
Patients with idiopathic myelofibrosis may have pancytopenia or bicytopenia and in that respect mimic patients with oligoblastic leukemia (myelodysplasia) (see Chap. 92). Contrariwise, patients with oligoblastic leukemia may rarely have intense fibrosis. Prominent splenomegaly is expected in patients with idiopathic myelofibrosis but not in patients with oligoblastic leukemia, which also helps to distinguish the former from the latter patients. The absence of a high frequency of teardrop shaped red cells, nucleated red cells, and striking aniso-poikilocytosis would mitigate against idiopathic myelofibrosis.
Since some patients with idiopathic myelofibrosis have platelet counts over 600,000 × 109/l, the diagnosis of primary thrombocythemia may be considered. The aniso-poikilocytosis, nucleated red cells, and myeloid immaturity in the blood film characteristic of myelofibrosis is not present in patients with thrombocythemia. Marrow fibrosis is usually insignificant in thrombocythemia, and splenic enlargement is often absent or slight. There is for these reasons usually a clear distinction between the two disorders.164,200
Hairy cell leukemia (see Chap. 99), when it is associated with shape abnormalities of red cells, pancytopenia, splenomegaly, and fibrotic marrow, can mimic idiopathic myelofibrosis closely. Usually, careful scrutiny of the blood and marrow by microscopy, histochemistry, and cell immunophenotype will show evidence of the abnormal mononuclear (hairy) cells that characterizes the disease.
Metastatic carcinoma, especially derived from carcinoma of the breast or prostate tumors201,202,203,204,205 and 206 or from disseminated mycobacterial infection, can induce reactive marrow fibrosis207 and occasionally simulate idiopathic myelofibrosis. The demonstration of metastatic carcinoma cells or mycobacteria in the marrow indicates the etiology. Other disorders reported with secondary myelofibrosis include mastocytosis,208,209 angioimmunoblastic lymphadenopathy,210 lymphoma,211 multiple myeloma,212,213,214,215,216 and 217 renal osteodystrophy,218 hypertrophic osteoarthropathy,219 gray platelet syndrome,220 systemic lupus erythematosus,148,149,150 and 151 polyarteritis nodosa,153 hypereosinophilic syndrome,221 tretinoin administration,222 neuroblastoma,223 giant lymph node hyperplasia,224 vitamin D deficiency rickets,225,226 Langerhans cell histiocytosis,227 and malignant histiocytosis.228 Correction or amelioration of the primary disorder can lead to disappearance of the marrow fibrosis.
Lymphoma,229,230 chronic lymphocytic leukemia,231 hairy cell leukemia,232 macroglobulinemia,233 amyloidosis,144,147 myeloma,234,235 malignant teratoma,236 and essential monoclonal gammopathy237 have been reported to coincide with idiopathic myelofibrosis.
All clonal hematopoietic diseases may have increased marrow reticulin fibers but only infrequently have collagen fibrosis.238 Acute megakaryoblastic leukemia is accompanied by intense marrow fibrosis (see Chap. 93). At least 25 percent of patients with polycythemia vera, whether treated by phlebotomy, alkylating agents, or 32P, develop a clinical state indistinguishable from idiopathic myelofibrosis during twenty years of observation239,240 and 241 (see Chap. 61).
Sideroblastic anemia has also been observed to progress to idiopathic myelofibrosis.242 Rarely, idiopathic myelofibrosis reverts to polycythemia vera, with disappearance of the marrow fibrosis.243,244 and 245
A very large proportion of asymptomatic patients will remain stable for years, not requiring specific treatment.2,54,55,56,57,58,59,60 and 61
Severe anemia may improve with androgen therapy in some patients.246,247,248 and 249 Testosterone, oxymethalone, and fluoxymesterone have been used but have virilizing effects, in addition to the potential for hepatic injury and other side effects. Danazol, 600 mg orally per day for weeks to months can be used. Patients on androgen therapy should have periodic assessment of liver size by physical examination, measurement of liver function tests, and if appropriate, ultrasound imaging to detect liver injury (e.g., peliosis) or tumors.250 Patients with significant hemolytic anemia may benefit from glucocorticoid therapy. A trial of prednisone, 25 mg/m2 per day, orally, can be tried. If tolerated, this dose can be continued for one to two months and thereafter tapered gradually. In children, high-dose glucocorticoid therapy has been reported to ameliorate marrow fibrosis and improve hematopoiesis.251,252
Serum erythropoietin levels are appropriate to the severity of anemia in patients with myelofibrosis.253 Use of erythropoietin to treat anemia has been largely unsuccessful.254,255
A variety of cytotoxic drugs have been used in the treatment of massive splenomegaly, thrombocytosis or constitutional symptoms. Hydroxyurea has become the most commonly used and preferred agent.256,257 and 258 Hydroxyurea can decrease the size of the spleen and liver; decrease or eliminate constitutional symptoms of night sweats or weight loss; and lead to an increase in hemoglobin concentration, a decrease of elevated platelet counts, and occasionally a decrease in the degree of marrow fibrosis. Patients with myelofibrosis often do not have the marrow tolerance to chemotherapy of patients with other chronic myeloproliferative diseases. Hydroxyurea can be administered in doses of 0.5 to 1.0 g per day or 1.0 to 2.0 g two to three times per week, orally, depending on the level of the pretreatment blood cell counts. Patients should be evaluated for dose adjustment at least every week for a month and, if appropriate, extended to every two weeks for two months. Thereafter, monthly evaluation of dose may be appropriate. Although alkylating agents, especially busulfan and other cytotoxic agents, have been used successfully they have largely been replaced by hydroxyurea.259
Ascites resulting from peritoneal hemopoietic implants has been treated by intraperitoneal cytarabine.260
Interferon alpha and interferon gamma act synergistically to inhibit myeloproliferation261 and are effective antiproliferative agents in chronic myelogenous leukemia (see Chap. 94). Although it has not been used extensively in idiopathic myelofibrosis, interferon alpha has been useful in treating splenic enlargement, bone pain, and thrombocytosis in selected patients.262 Trials comparing interferon therapy with chemotherapy have not been reported. Hydroxyurea is easier to use and has less frequent side effects than interferon.
Debilitating bone pain can be a vexing problem in some patients with osteosclerosis and periostitis. A report of dramatic improvement in bone pain and hematopoiesis after etidronate, 6 mg/kg, on alternate months may indicate the potential usefulness of this family of drugs.264
There are five situations in which radiotherapy can be useful for patients with idiopathic myelofibrosis: In the presence of (1) severe splenic pain (splenic infarctions) or (2) massive splenic enlargement with a contraindication to splenectomy (e.g., thrombocytosis),264,265 and 266 doses of 50 to 200 rad (0.5 to 2 Gy) to the spleen can produce an amelioration of pain. The other situations in which radiation may be useful are (3) ascites resulting from myeloid metaplasia of the peritoneum;267 (4) focal areas of severe bone pain (periostitis or the osteolysis of a granulocytic sarcoma);161,268 and (5) extramedullary fibrohemopoietic tumors,76 especially of the epidural space.104
Splenectomy is important in the management of idiopathic myelofibrosis.269,270,271 and 272,303 The major indications for splenectomy include (1) painful enlarged spleen, (2) excessive transfusion requirements or refractory hemolytic anemia, (3) severe thrombocytopenia, and (4) portal hypertension.
Patients who have a prolonged bleeding time or coagulation times are at serious risk of hemorrhage with surgery and should not have the procedure unless these abnormalities can be corrected by platelet transfusion or factor replacement therapy. Evidence of low-grade intravascular coagulation, such as elevated D-dimer levels, may require prophylactic heparin therapy and platelet transfusion should there be excessive bleeding. In one series 50 patients had splenectomy: 26 of 27 patients splenectomized for pain, 5 of 9 patients splenectomized for refractory hemolysis, 4 of 10 patients splenectomized for refractory thrombocytopenia, and 4 of 4 patients splenectomized for portal hypertension had improvement.271
Removal of the spleen in patients with idiopathic myelofibrosis may be difficult. The spleen is usually adherent to neighboring serosal surfaces and structures and has numerous collateral vessels and very dilated splenoportal arteries and veins. Immediate postoperative mortality is a function of surgical experience and skill and of the rapidity of recognition of postoperative complications. In experienced hands, perioperative mortality should be less than 10 percent. Postoperative morbidity from hemorrhage, subphrenic hematoma, subphrenic abscess, injury to the tail of the pancreas, pancreatic fistulas, or portal vein stump thrombosis occurs in about 30 percent of patients. Later, postoperative changes include liver enlargement,273 extramedullary hemopoietic tumors,115,119 and a decrease in teardrop-shaped red cells.274 Postoperative liver enlargement and thrombocytosis have responded to treatment with cladribine.275 Anagrelide may also be useful for exaggerated thrombocytosis (see Chap. 118). The morbidity and mortality from splenectomy and the modest extension of life on the average has led to increasing conservatism in its use.276 Splenectomy, however, can improve the state of patients who are selected carefully and in a timely fashion.
Five patients with idiopathic myelofibrosis were among 91 patients who had subtotal splenectomy, preserving the upper pole of the spleen and its blood supply. No surgical mortality occurred, but details of outcome were not reported.277
Patients who are operated on for portal hypertension and bleeding varices or refractory ascites should have circulatory dynamic studies performed at the time of surgery. In patients in whom the hepatic wedge-pressure elevations are a result of the markedly increased blood flow from the spleen to the liver, the preferred treatment procedure for portal hypertension is splenectomy. In those patients who have portal hypertension as a result of intrahepatic block or hepatic vein thrombosis, a splenorenal shunt is usually performed.278
Several experimental forms of therapy have been used in a small number of patients. Hematologic remission has been described in one case of myelofibrosis treated by bilateral iliac-crest marrow curettage.279
Investigative approaches to the disease include the use of agents that prevent collagen formation, such as monoamine oxidase inhibitors and lysylaldehyde chelators such as dehydroproline.280
1,25-Dihydroxyvitamin D therapy was associated with improvement of patients with myelofibrosis, although hypercalcemia and hypophosphatemia may prevent continued use.281 The mechanism of action could relate to a profound antiproliferative effect of 1,25-dihydroxyvitamin D on megakaryocytes, which are the putative source of most of the fibroblast activation factors. In two other reports no benefit was found from administration of this vitamin D analog.282,283 1,25-Dihydroxycholecalciferol has also been reported to ameliorate myelofibrosis.284 Single cases of improvement in hematopoiesis and decrease in osteosclerosis after intravenous immune globulin285 and sustained improvement in anemia after cyclosporine286 have been reported.
Marrow transplantation therapy, which is efficacious in acute megakaryocytic leukemia with intense myelofibrosis, could be used in appropriate candidates who are under the age of 40 and have a histocompatible sibling.287,288 and 289 Patients engraft at a rate similar to patients with hematologic diseases without marrow fibrosis289 (see Chap. 18).
The rate of progression of the disease has been associated with at least ten variables measured at the time of diagnosis. Shorter survival has been associated with older age, severity of anemia, severity of thrombocytopenia, exaggerated leukocytosis or leukopenia, the proportion of blast cells in the blood, degree of liver enlargement, extent of marrow fibrosis, abnormal clonal cytogenetic abnormalities, and constitutional symptoms of fever, sweating, or weight loss at the time of diagnosis. Each retrospective study has found a different subset of these factors to be significant prognostic factors. The most consistent predictive variables appear to be advanced age, severity of anemia, and clonal cytogenetic abnormality at the time of diagnosis, each of which represents a poor prognostic indicator.57,58,59 and 60,163,164,191,290
The median survival of all patients with idiopathic myelofibrosis is approximately 5 years from the time of diagnosis.57,58,59 and 60 The 5-year survival is about forty percent of that expected for healthy age- and sex-matched controls.2,55,291 Retrospective analysis of prognostic variables permits stratification of patients into slowly progressive and rapidly progressive cohorts.55,57,58 and 59,163,167,291
The major causes of death are infection, hemorrhage, postsplenectomy mortality, and acute leukemic transformation).2,54,55 and 56,292,293 and 294,301 Acute leukemia occasionally may be preceded by the development of granulocytic sarcomas.160,269,295 Evolution of the disease to acute lymphocytic leukemia or lymphoma also may occur.296,297 An increased risk of progression to leukemia has been reported in splenectomized patients.298 Rare spontaneous remissions of apparent idiopathic myelofibrosis have been documented.299,300

Heuck G: Zwei Fälle von Leukämie mit eigenthümlichem Blut-resp Knochenmarksbefund. Virchows Arch (Pathol Anat) 78:475, 1879.

Silverstein MN: Agnogenic Myeloid Metaplasia. Publishing Science, Boston, 1975.

Heller EL, Lewisohn MG, Palin WE: Aleukemic myelosis, chronic nonleukemic myelosis, agnogenic myeloid metaplasia, osteosclerosis, leukoerythroblastic anemia, and synonymous designations. Am J Pathol 23:327, 1947.

Yan X-Q, Lacey D, Hill D, et al: A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand). Blood 88:402, 1996.

Aksoy M, Erdem S, Dincol G: Two rare complications of chronic benzene poisoning: myeloid metaplasia and paroxysmal nocturnal hemoglobinuria. Blut 30:255, 1975.

Hu H: Benzene-associated myelofibrosis. Ann Intern Med 106:171, 1987.

Tondel M, Perrson B, Carstensen J: Myelofibrosis and benzene exposure. Occup Med 45:31, 1995.

Anderson RE, Hoshino T, Yamamoto T: Myelofibrosis with myeloid metaplasia in survivors of the atomic bomb in Hiroshima. Ann Intern Med 60:1, 1964.

Dungworth DL, Goldman M, Switzer JW, et al: Development of a myeloproliferative disorder in beagles continuously exposed to 90Sr. Blood 34:610, 1969.

Jacobson RS, Salo A, Fialkow PS: Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51:189, 1978.

Kahn A, Bernard JF, Cottreau D, et al: A deficient G-6-PD variant with hemizygous expression in blood cells of a woman with primary myelofibrosis. Humangenetick 30:41, 1975.

Sato Y, Suda T, Suda J, et al: Multilineage expression of haemopoietic precursors with an abnormal clone in idiopathic myelofibrosis. Br J Haematol 64:657, 1986.

Kreipe H, Jaquet K, Falgner J, et al: Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood 78:1814, 1991.

Tsukamoto N, Morita K, Maehara T, et al: Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes. Br J Haematol 86:253, 1994.

Buschle M, Janssen JWG, Drexler H, et al: Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: Clonal analysis of a case characterized by a N-ras gene mutation. Leukaemia 2:658, 1988.

Lebowitz P, Papac R, Ghosh PK: Impaired retinoblastoma susceptibility (Rb) gene expression in agnogenic myeloid metaplasia. Blood 76(suppl 1):236A, 1990.

Prockop DJ, Kivirikko KI, Tuderman L, et al: The biosynthesis of collagen and its disorders. N Engl J Med 301:13, 1979.

Bauermeister DE: Quantitation of bone marrow reticulin: A normal range. Am J Clin Pathol 56:24, 1971.

Ivànyi JL, Mahunka M, Papp A, Telek B: Prognostic significance of bone marrow reticulum fibers in idiopathic myelofibrosis: evolution of clinicopathological parameters in a scoring system. Hematologia 26:75, 1994.

McCarthy DM: Annotation: Fibrosis of the bone marrow: Content and causes. Br J Haematol 59:1, 1985.

Apaja-Sarkkinen M, Autio-Harmainen H, Alavaikko M, et al: Immunohistochemical study of basement membrane proteins and type III procollagen in myelofibrosis. Br J Haematol 63:571, 1986.

Hasselbalch H, Junker P, Lisse I, et al: Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders. Am J Hematol 23:101, 1986.

Reilly JT: Pathogenesis of idiopathic myelofibrosis: Role of growth factors. J Clin Pathol 45:461, 1992.

Charron D, Robert L, Couty MC, Binet JL: Biochemical and histological analysis of bone marrow collagen in myelofibrosis. Br J Haematol 41:151, 1979.

Gay S, Gay RE, Prohal JT: Immunohistological studies of bone marrow collagen, in Myelofibrosis and the Biology of Connective Tissue, edited by P Berk, H Castro-Malaspina, LR Wasserman, pp 291–306. Liss, New York, 1984.

Hasselbalch H, Junker P, Horslev-Patersen K, et al: Procollagen type III amino-terminal peptide in serum in idiopathic myelofibrosis and allied conditions. Am J Hematol 33:18, 1990.

Reilly JT, Nash JRG, Mackie MJ, McVerry BA: Endothelial cell proliferation in myelofibrosis. Br J Haematol 60:625, 1985.

Baglin TP, Crocker MA, Timmins A, et al: Bone marrow hypervascularity in patients with myelofibrosis identified by infrared thermography. Clin Lab Haematol 13:341, 1991.

Dolan G, Forrest P, Eastham J, et al: Serum laminin, procollagen terminal peptide III and thrombocyte platelet derived growth factor concentrations in idiopathic myelofibrosis. Br J Haematol 77(suppl 1):73, 1991.

Reilly JT, Nash JRG, Mackie MJ, McVerry BA: Immunoenzymatic detection of fibronectin in normal and pathological haemopoietic tissue. Br J Haematol 59:497, 1985.

Hasselbalch H, Clemmensen I: Plasma fibronectin in idiopathic myelofibrosis and related chronic myeloproliferative disorders. Scand J Clin Lab Invest 47:429, 1987.

Soini Y, Kamel D, Apaja-Sarkkinen M, et al: Tenascin immunoreactivity in normal and pathological bone marrow. J Clin Pathol 46:218, 1993.

Reilly JT, Nash JRG: Vitronectin (serum spreading factor): Its localization in normal and fibrotic tissue. J Clin Pathol 41:1269, 1988.

Wang JC, Wong C, Kao WW: Immunoreactive prolylhydroxylase in patients with primary and secondary myelofibrosis. Br J Haematol 65:171, 1987.

Barosi G, Costa A, Liberato LN, et al: Serum procollagen III peptide level correlates with disease activity in myelofibrosis with myeloid metaplasia. Br J Haematol 72:16, 1989.

Hochweiss S, Fruchtman S, Hahn EG, et al: Increased serum procollagen III amino-terminal peptide in myelofibrosis. Am J Hematol 15:343, 1983.

Hasselbalch H, Junker P, Lisse I, et al: Circulating hyaluronan in the myelofibrosis/osteomyelosclerosis syndrome and other myeloproliferative disorders. Am J Hematol 36:1, 1991.

Thiele J, Kvasnicka HM, Fischer R, Diehl V: Clinicopathological impact of the interactivity between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update. Leuk Lymph 24:463, 1997.

Rosenfeld M, Keating A, Bowen-Pope BF, et al: Responsiveness of the in vitro hematopoietic microenvironment to platelet-derived growth factor. Leuk Res 9:427, 1985.

Bernabei PA, Arcangeli A, Casini M, et al: Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease. Br J Haematol 63:353, 1986.

Thiele J, Rompick V, Wagner S, Fischer R: Vascular architecture and collagen type IV in primary myelofibrosis and polycythemia vera. Br J Haematol 80:227, 1992.

Johnston JB, Dalal BI, Israels SJ, et al: Deposition of transforming growth factor-b in the marrow in myelofibrosis, and the intracellular localization and secretion of TGF-b by leukemic cells. Am J Clin Pathol 103:574, 1995.

Martré M-C: TGF-b and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leuk Lymph 20:39, 1995.

Martré M-C, LeBousse-Kerdiles M-C, Romquin N, et al: Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 97:441, 1997.

Dalley A, Smith JM, Reilly JT, MacNeil S: Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation. Br J Haematol 93:856, 1996.

Nathan C: Secretory products of macrophages. J Clin Invest 79:319, 1987.

Burstein SA, Malpass TW, Yee E, et al: Platelet factor-4 excretion in myeloproliferative disease: Implication for the aetiology of myelofibrosis. Br J Haematol 57:383, 1984.

Kvasnica HM, Thiele J, Amend T, Fischer R: Three-dimensional reconstruction of histiologic structures in human bone marrow from serial sections of trephine biopsies. Anal Quant Cytol Hist 16:159, 1994.

Reilly JT, Nash JR, Mackie MJ, et al: Endothelial cell proliferation in myelofibrosis. Br J Haematol 60:625, 1985.

Charbord P: Increased vascularity of bone marrow in myelofibrosis. Br J Haematol 62:595, 1986.

VanDyke D, Anger HO, Parker H, et al: Markedly increased bone blood flow in myelofibrosis. J Nucl Med 12:506, 1971.

Hotta T, Utsumi M, Katoh T, et al: Granulocytic and stromal progenitors in the bone marrow of patient with primary myelofibrosis. Scand J Haematol 34:251, 1985.

Greenberg BR, Woo L, Veomett JC, et al: Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis. Br J Haematol 66:487, 1987.

Ward HP, Block MH: The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with myeloproliferative syndrome. Medicine 50:357, 1971.

Varki A, Lottenberg R, Griffith R, et al: The syndrome of idiopathic myelofibrosis. Medicine 62:353, 1983.

Hasselbalch H: Idiopathic myelofibrosis. Am J Hematol 34:291, 1990.

Kvasnicka H-M, Thiele J, Werden C, et al: Prognostic factors in idiopathic (primary) osteo-myelofibrosis. Cancer 80:708, 1997.

Cervantes F, Pereira A, Esteve J, et al: Identification of “short-lived” and “long-lived” patients at presentation of idiopathic myelofibrosis. Br J Haematol 97:635, 1997.

Dupriez B, Morel P, Demory JL, et al: Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88:1013, 1996.

Rupoli S, DaLio L, Sisti S, et al: Primary myelofibrosis: a detailed analysis of the clinicopathologic variables influencing survival. Ann Hematol 68:205, 1994.

Ozen S, Ferhanoglu B, Senocak M, Tüzüner N: Idiopathic myelofibrosis (agnogenic myeloid metaplasia). Leuk Res 21:125, 1997.

Shalev O, Goldfarb A, Ariel I, et al: Myelofibrosis in young adults. Acta Haematol 70:396, 1983.

Selehar M, Prentice HG, Poyat U, et al: Idiopathic myelofibrosis in children. Br J Haematol 93:394, 1996.

Sekhar M, Prentice HG, Popat U, et al: Idiopathic myelofibrosis in children. Br J Haematol 93:394, 1996.

Cohn SL, Cohn RA, Chou P, et al: Infantile myelofibrosis with nephromegaly secondary to myeloid metaplasia. Clin Pediatrics 30:59, 1991.

Mallouh AA, Sa’di AR: Agnogenic myeloid metaplasia in children. Am J Dis Child 146:965, 1992.

Kaufman S, Briere J, Bernard J: Familial myeloproliferative syndromes: Study of 6 families and review of literature. Nouv Rev Fr Hematol 20:1, 1978.

Péres-Encinas M, Bello JL, Perez-Crespo S, et al: Familial myeloproliferative syndrome. Am J Hematol 46:225, 1994.

Caughman W, Stern R, Haynes H: Neutrophilic dermatosis of myeloproliferative disorders: Atypical forms of pyoderma gangrenosum and Sweet’s syndrome associated with myeloproliferative disorders. J Am Acad Dermatol 9:751, 1983.

Gibson LE, Dicken CH, Flach DB: Neutrophilic dermatoses and myeloproliferative disease: Report of two cases. Mayo Clin Proc 60:735, 1985.

Su WPD, Alegre VA, White WL: Myelofibrosis discovered after diagnosis of Sweet’s syndrome. Int J Dermatol 29:201, 1990.

Kanel KT, Kroboth FJ, Swartz WM: Pyoderma gangrenosum with myelofibrosis. Am J Med 82:1031, 1987.

Loewy G, Matthew A, Distenfeld A: Skin manifestations of agnogenic myeloid metaplasia. Am J Hematol 45:167, 1994.

King BF, Kopecky KK, Baker MK, et al: Extramedullary hematopoiesis in the adrenal glands: CT characteristics. J Comput Assist Tomogr 11:342, 1987.

Redlin L, Francis RS, Orlando MM: Renal abnormalities in agnogenic myeloid metaplasia. Radiology 121:605, 1976.

Shaver RW, Close FC: Extramedullary hemopoiesis in myeloid metaplasia. Am J Radiol 137:874, 1981.

Williams ME, Innes DJ, Hutchison WT, et al: Extramedullary hematopoiesis: A cause of severe generalized lymphadenopathy in agnogenic myeloid metaplasia. Arch Intern Med 145:1308, 1985.

Sharma BK, Pounder RE, Cruse JP, et al: Extramedullary haemopoiesis in the small bowel. Gut 27:873, 1986.

MacKinnon S, McNicol AM, Lee FD, et al: Myelofibrosis complicated by intestinal extramedullary haemopoiesis and acute small bowel obstruction. J Clin Pathol 39:677, 1986.

Soloman D, Goodman H, Jacobs P: Rectal stenosis due to extramedullary hematopoiesis. Clin Radiol 49:726, 1994.

Sunderland K, Barratt J, Pidcock M: Extramedullary hemopoiesis arising in the gut mimicking carcinoma of the cecum. Pathol 26:62, 1994.

Brooks JJ, Krugman DT, Danjanor I: Myeloid metaplasia presenting as a breast mass. Am J Surg Pathol 4:281, 1980.

Martinelli G, Santini D, Bazzocchi F, et al: Myeloid metaplasia of the breast: A lesion which clinically mimics carcinoma. Virchows Arch 401:203, 1983.

Zonderland HM, Michiels JJ, ten Kate FJW: Mammographic and sonographic demonstration of extramedullary hematopoiesis of the breast. Clin Radiol 44:64, 1991.

Yusen RD, Kollef MH: Acute respiratory failure due to extramedullary hematopoiesis. Chest 108:1170, 1995.

Asakura S, Colby T: Agnogenic myeloid metaplasia with extramedullary hemopoiesis and fibrosis in the lung. Chest 105:1866, 1994.

Pierard GE: Cutaneous hematopoiesis and myelofibrosis. Ann Pathol 7:73, 1987.

Mizoguchi M, Kawa Y, Minami T, et al: Cutaneous extramedullary hematopoiesis in myelofibrosis. J Am Acad Dermatol 22:351, 1990.

Heinicke MH, Zarrabi MH, Gorevic PD: Arthritis due to synovial involvement by extramedullary haematopoiesis in myelofibrosis with myeloid metaplasia. Ann Rheum Dis 42:196, 1983.

Leoni F, Fabbri R, Pascarella A, et al: Extramedullary hematopoiesis in thyroid multinodular goiter preceding clinical evidence of agnogenic myeloid metaplasia. Histopathology 28:559, 1996.

Humphrey PA, Vollmer RT: Extramedullary hematopoiesis in the prostate. Am J Surg Pathol 15:486, 1991.

Balogh K, O’Hara CJ: Myeloid metaplasia masquerading as a urethral caruncle. J Urol 135:789, 1986.

Oesterling JE, Keating JP, Leroy AJ, et al: Idiopathic myelofibrosis with myeloid metaplasia involving the renal pelvis, ureters and bladder. J Urol 147:1360, 1992.

Gryspeerdt S, Oyen R, Van Hoe L, et al: Extramedullary hematopoiesis encasing the pelvicalyceal system. Ann Hematol 71:53, 1995.

Perazella MA, Buller GK: Nephrotic syndrome associated with agnogenic myeloid metaplasia. Am J Nephrol 14:223, 1994.

Holt SG, Field P, Carmichael P, et al: Extramedullary haemopoiesis in the renal parenchyma as a cause of acute renal failure in myelofibrosis. Nephrol Dial Transplant 10:1438, 1995.

Brown JA, Gomez-Leon G: Subdural hemorrhage secondary to extramedullary hematopoiesis in postpolycythemic myeloid metaplasia. Neurosurg 14:588, 1984.

Cornfield DB, Shipkin P, Alluvia A, et al: Intracranial myeloid metaplasia: Diagnosis by CT and Fe52 scans and treatment by cranial irradiation. Am J Hematol 15:273, 1983.

Lundh B, Brandt L, Cronqvist S, et al: Intracranial myeloid metaplasia in myelofibrosis. Scand J Haematol 28:91, 1982.

Cameron WR, Ronnert M, Brun A: Extramedullary hematopoiesis of CNS in postpolycythemic myeloid metaplasia. N Engl J Med 305:765, 1981.

Ligumski M, Polliack A, Benbassat J: Metaplasia of the central nervous system in patients with myelofibrosis and agnogenic myeloid metaplasia. Am J Med Sci 275:99, 1979.

Stahl SM, Ellinger G, Baringer JR: Progressive myelopathy due to extramedullary hematopoiesis. Ann Neurol 5:485, 1979.

Cook G, Sharp RA: Spinal cord compression due to extramedullary haemopoiesis in myelofibrosis. J Clin Pathol 47:464, 1994.

Price F, Bell H: Spinal cord compression due to extramedullary hematopoiesis: Successful treatment in a patient with long-standing myelofibrosis. JAMA 253:2876, 1985.

Ohtsubo M, Hayaski K, Fukushima T, et al: Intracranial extramedullary haematopoiesis in postpolycythemia myelofibrosis. Br J Radiol 67:299, 1994.

Urman M, O’Sullivan RA, Nugent RA, Lentle BC: Intracranial extramedullary hematopoiesis. Clin Nucl Med 16:431, 1991.

Lanir A, Aghai E, Simon JS, et al: MR imaging in myelofibrosis. J Comput Assist Tomogr 10:634, 1986.

Koch BL, Bisset GS, Bisset RR, Zimmer MB: Intracranial extramedullary hematopoiesis: MR findings with pathologic correlation. Am J Roentgenol 162:1419, 1994.

Bartlett RP, Greipp PR, Tefferi A, et al: Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. Mayo Clin Proc 70:1165, 1995.

Knobel B, Melamud E, Virage I, Meytes D: Ectopic medullary hematopoiesis as a cause of ascites in agnogenic myeloid metaplasia. Acta Haematol 89:104, 1993.

Lioté F, Yeni P, Teillet-Thiebaud F, et al: Ascites revealing peritoneal and hepatic extramedullary hematopoiesis with peliosis in agnogenic myeloid metaplasia. Am J Med 90:111, 1991.

Vilaseca J, Arnau JM, Tallada N, et al: Agnogenic myeloid metaplasia presenting as massive pericardial effusion due to extramedullary hematopoiesis. Acta Haematol (Basel) 73:239, 1985.

Haedersdal C, Hasselbalch H, Devantier A, et al: Pericardial haematopoiesis with tamponade in myelofibrosis. Scand J Haematol 34:270, 1985.

Imam TH, Doll DC: Acute cardiac tamponade associated with pericardial extramedullary hematopoieses in agnogenic myeloid metaplasia. Acta Haematol 98:42, 1997.

Nagler A, Brenner B, Argov S, et al: Postsplenectomy pericardial effusion in two patients with myeloid metaplasia. Arch Intern Med 146:600, 1986.

Pedio G, Krause M, Jansova I: Megakaryocytes in ascitic fluid in a case of agnogenic myeloid metaplasia (letter). Acta Cytol 29:89, 1985.

Silverman JF: Extramedullary hematopoietic ascitic fluid cytology in myelofibrosis. Am J Clin Pathol 84:125, 1985.

Stephenson RW, Britt DA, Schumann GB: Primary cytodiagnosis of peritoneal extramedullary hematopoiesis. Diag Cytopathol 2:241, 1986.

Hocking WG, Lazar GS, Lipsett JA, et al: Cutaneous extramedullary hematopoiesis following splenectomy for idiopathic myelofibrosis. Am J Med 76:956, 1984.

Partanen S, Ruutu T, Jubonen E, et al: Effect of splenectomy on circulating haematopoietic progenitors in myelofibrosis. Scand J Haematol 37:87, 1986.

Chubachi A, Wakui H, Miura I, et al: Extramedullary megakaryoblastic tumors following an indolent phase of myelofibrosis Leuk Lymph 17:351, 1995.

Chan ACL, Kwong Y-L, Lam CCK: Granulocytic sarcoma megakaryoblastic differentiation complicating chronic idiopathic myelofibrosis. Hum Pathol 27:417, 1996.

Oishi N, Swisher SN, Stormont JM, et al: Portal hypertension in myeloid metaplasia. Arch Surg 81:80, 1960.

Rosenbaum DL, Murphy GW, Swisher SN: Hemodynamic studies of the portal circulation in myeloid metaplasia. Am J Med 41:360, 1966.

Jacobs P, Maze S, Tayob F, et al: Myelofibrosis, splenomegaly, and portal hypertension. Acta Haematol 74:45, 1985.

Degott C, Carpon JP, Bettan L, et al: Myeloid metaplasia, perisinusoidal fibrosis, and nodular regenerative hyperplasia of the liver. Liver 5:276, 1985.

Bioulac-Sage P, Roux D, Quinton A, et al: Ultrastructure of sinusoids in patients with agnogenic myeloid metaplasia. J Submicrosc Cytol 18:815, 1986.

Roux D, Merlio JP, Quinton A, et al: Agnogenic myeloid metaplasia, portal hypertension and sinusoidal abnormalities. Gastroenterology 92:1067, 1987.

Tsao MS: Hepatic sinusoidal fibrosis in agnogenic myeloid metaplasia. Am J Clin Pathol 91:302, 1989.

Valla d, Casadevall N, Huisse MG, et al: Etiology of portal vein thrombosis in adults. Gastroenterology 94:1063, 1988.

Boivin P, Bernard JF, Hakim J, et al: Anomalies immunitaires au cours de splenomegalies myeloides myelosclerose. Acta Haematol (Basel) 51:91, 1974.

Lang JM, Oberling F, Mayer S, et al: Autoimmunity in primary myelofibrosis. Biomedicine 25:39, 1976.

Barge J, Slabodshy-Brousse N, Bernard JF: Histoimmunology of myelofibrosis: A study of 100 cases. Biomedicine 29:73, 1978.

Vellenga E, Mulder N, The T, et al: A study of the cellular and humoral immune response in patients with myelofibrosis. Clin Lab Haematol 4:239, 1982.

Rondeau E, Solal-Celigny P, Dhermy D, et al: Immune disorders in agnogenic myeloid metaplasia: Relations to myelofibrosis. Br J Haematol 53:467, 1983.

Gordon B: Immunological abnormalities in myelofibrosis. Prog Clin Biol Res 154:455, 1984.

Khumbanonda M, Horowitz HI, Eyster ME: Coombs’ positive hemolytic anemia in myelofibrosis with myeloid metaplasia. Am J Med Sci 258:89, 1969.

Schreiber ZA: Immune thrombocytopenia in postpolythemic myelofibrosis. Am J Hematol 54:146, 1997.

Seelen MAJ, de Meijer PHEM, Posthuma EF, Meinders AE: Myelofibrosis and thrombocytopenic purpura. Ann Hematol 75:129, 1997.

Wang JC, Wang A: Plasma soluble interleukin-2 receptor in patients with primary myelofibrosis. Br J Haematol 86:380, 1994.

Leoni P, Rupoli S, Salvi A, et al: Antibodies against terminal galactosyl alpha(1–3) galactose epitopes in patients with idiopathic myelofibrosis. Br J Haematol 85:313, 1993.

Bernhardt B, Valleta M: Lupus anticoagulant in myelofibrosis. Am J Med Sci 272:229, 1976.

Cappio FC, Vigliani R, Novarino A, et al: Idiopathic myelofibrosis: A possible role for immune-complexes in the pathogenesis of bone marrow fibrosis. Br J Haematol 49:17, 1981.

Akikusa B, Komatsu T, Kondo Y, et al: Amyloidosis complicating idiopathic myelofibrosis. Arch Pathol Lab Med 111:525, 1987.

Hasselbalch H, Nielsen H, Berild D, et al: Circulating immune complexes in myelofibrosis. Scand J Haematol 34:177, 1985.

Gordon BR, Coleman M, Kohen P, et al: Immunologic abnormalities in myelofibrosis with activation of the complement system. Blood 58:904, 1981.

Ferhanoglu B, Erzin Y, Baslar Z, Tüzüner HAN: Secondary amyloidosis in the course of idiopathic myelofibrosis. Leuk Res 21:897, 1997.

El Mouzan MI, Ahmed MAM, Saleh MAF, et al: Myelofibrosis and pancytopenia in systemic lupus erythematosus. Am J Med 81:935, 1986.

Matsouka CH, Lioouris J, Andrianokis A: Systemic lupus erythematosus and myelofibrosis. Clin Rheumatol 8:402, 1989.

Paquette RL, Meshkinpour A, Rosen PJ: Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. Medicine 73:145, 1994.

Ramakrishna R, Kyle PW, Day PJ, Mansharan A: Evan’s syndrome, myelofibrosis and systemic lupus erythematosus: role of procollagens in myelofibrosis. Pathol 27:255, 1995.

Aharon A, Levy Y, Bar-Dayan Y, et al: Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 6:408, 1997.

Von Knorring J, Selroos OW, Wegelius O: Myeloid metaplasia in disseminated vascular disease. Acta Med Scand 195:137, 1974.

Connelly TJ, Abruzzo JL, Schwab RH: Agnogenic myeloid metaplasia with polyarteritis. J Rheumatol 9:954, 1982.

Ben-Chetrit E, Gross DJ, Ikon E, et al: The association between auto-immunity and agnogenic myeloid metaplasia. Scand J Haematol 31:410, 1983.

Hasselbalch H, Jans H, Nielsen PL: A distinct subtype of idiopathic myelofibrosis with bone marrow features mimicking hairy cell leukemia: Evidence of an autoimmune pathogenesis. Am J Hematol 25:225, 1987.

Thiele J, Chen Y-S, Kvasnicka H-M, et al: Evolution of fibro-osteosclerotic bone marrow lesions in primary (idiopathic) osteomyelofibrosis—a histomorphometric study on sequential trephine biopsies. Leuk Lymph 14:163, 1994.

Coindre JM, Reiffers J, Goussot JF, et al: Histomorphometric analysis of sclerotic bone from idiopathic myeloid metaplasia. J Pathol 144:163, 1984.

Cassi E, DePaoli A, Tosi A, et al: Pure osteolytic lesions in myelofibrosis: Report of 2 cases. Haematologica 70:178, 1985.

Fayemi AO, Gerber MA, Cohen I, et al: Myeloid sarcoma. Cancer 32:253, 1973.

Yu JS, Greenway G, Resnick D: Myelofibrosis associated with prominent periosteal bone apposition. Clin Imaging 18:89, 1994.

Barosi G, Cazzoli M, Frassoni F: Erythropoiesis in myelofibrosis with myeloid metaplasia: Recognition of different classes of patients by erythrokinetics. Br J Haematol 48:263, 1981.

Barosi G, Berzuinic C, Liberato LN, et al: A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 70:397, 1988.

Thiele J, Kvasnicka H-M, Werden C, et al: Idiopathic primary osteomyelofibrosis. Leuk Lymph 22:303, 1996.

Njoku OS, Lewis SM, Catovsky D, et al: Anaemia in myelofibrosis: Its value in prognosis. Br J Haematol 54:79, 1983.

Howarth JE, Waters HM, Hyde K, Geary CG: Detection of erythroid hypoplasia in myelofibrosis using erythrokinetic studies. J Clin Path 42:1250, 1989.

Thiele J, Windecker R, Kvasnicka HM, et al: Erythropoiesis in primary (idiopathic) osteomyelofibrosis. Am J Hematol 46:36, 1994.

Bird GW, Wingham J, Richardson SG: Myelofibrosis, autoimmune haemolytic anaemia and Tn-polyagglutinability. Haematologia 18:99, 1985.

Kuo CY, VanVoolen GA, Morrison AN: Primary and secondary myelofibrosis: Its relationship to the PNH-like defect. Blood 40:875, 1972.

Veer A, Kosciolek BA, Bauman AW, et al: Acquired hemoglobin H disease in idiopathic myelofibrosis. Am J Hematol 6:199, 1979.

Barosi G, Baraldi A, Cassola M, et al: Red cell aplasia in myelofibrosis with myeloid metaplasia. Cancer 52:1290, 1983.

Silverstein MN, Elveback LR: Leukocyte alkaline phosphatase in agnogenic myeloid metaplasia. Am J Clin Pathol 61:307, 1974.

Douer D, Fabian I, Cline MJ: Circulation pluripotent haemopoietic cells in patients with myeloproliferative disorders. Br J Haematol 54:373, 1983.

Partanen S, Ruutu T, Vuopio P: Circulating haematopoietic progenitors in myelofibrosis. Scand J Haematol 29:325, 1982.

Wang JC, Cheung CP, Ahmed F, et al: Circulating granulocyte and macrophage progenitor cells in primary and secondary myelofibrosis. Br J Haematol 54:301, 1983.

Kornberg A, Fibach E, Treves A, et al: Circulating erythroid progenitors in patients with “spent” polycythaemia vera and myelofibrosis with myeloid metaplasia. Br J Haematol 52:573, 1982.

Tinggaard-Pedersen N, Laursen B: Megakaryocytes in cubital venous blood in patients with chronic myeloproliferative diseases. Scand J Haematol 30:50, 1983.

Marquetty C, Labro-Bryskier MT, Perianin A, et al: Impaired metabolic activity of phagocytosis neutrophils in agnogenic osteomyelofibrosis with splenomegaly. Am J Med 16:243, 1984.

Perianin A, Labro-Bryskier MT, Marquetty C, et al: Glutathione reductase and nitroblue tetrazolium reduction deficiencies in neutrophils of patients with primary idiopathic myelofibrosis. Clin Exp Immunol 57:244, 1984.

Murphy S, Davis JL, Walsh PN, et al: Template bleeding time and clinical hemorrhage in myeloproliferative disease. Arch Intern Med 138:1251, 1978.

Malpass TW, Savage B, Hanson SR, et al: Correlation between bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders. J Lab Clin Med 103:894, 1984.

Cunietti E, Gandini R, Marcaro G, et al: Defective platelet aggregation and increased platelet turnover in patients with myelofibrosis and other myeloproliferative diseases. Scand J Haematol 26:339, 1981.

Schafer AL: Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl J Med 306:381, 1982.

Shafer AL: Bleeding and thrombosis in the myeloproliferative disorders. Blood 64:1, 1984.

Barbui T, Cortelazzo S, Viero P, et al: Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: Relationship to platelet number and function. Eur J Cancer Clin Oncol 19:1593, 1983.

Thiele J, Lorenzen J, Manich B, et al: Apoptosis (programmed cell death) in idiopathic (primary) osteo-/myelofibrosis. Acta Haematol 97:137, 1997.

Thiele J, Holgado S, Choritz H, et al: Chronic megakaryocyte-granulocytic myelosis—an electron microscope study including freeze-fracture. Virchows Arch[A] 375:129, 1977.

Miller JB, Testa JR, Lindgren V, et al: The patterns and clinical significance of karyotypic abnormalities in patients with idiopathic polycythemic myelofibrosis. Cancer 55:582, 1985.

Damor JL, Dupriez B, Fenaux P, et al: Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia. Blood 72:855, 1988.

Nakamura H, Sadamori N, Mine M, et al: Effects of short-term liquid culture of peripheral blood mononuclear cells with recombinant human granulocyte or granulocyte-macrophage colony-stimulating factor in cytogenetic studies of myelofibrosis with myeloid metaplasia. Leukemia 6:853, 1992.

Reilly JT, Snowden JA, Spearing RL, et al: Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis. Br J Haematol 98:96, 1997.

Forrester RH, Louro JM: Philadelphia chromosome abnormality in agnogenic myeloid metaplasia. Ann Intern Med 64:622, 1966.

Weda F, Takashima T, Suzuki M, Kadoya M: MR diagnosis of myelofibrosis Radiat Med 12:135, 1994.

Amano Y, Onda M, Amano M, Kumazaki T: Magnetic resonance imaging of myelofibrosis. STIR and gadolinium-enhanced MR images. Clin Imaging 21:264, 1997.

Gilbert HS, Ginsberg H, Fagerstrom R, Brown WV: Characterization of hypocholesterolemia in myeloproliferative diseases. Am J Med 71:595, 1981.

Naggar L, Jaeger P, Burckhardt P, et al: Hypocalcemia and myelofibrosis: An unrecognized association. Schweiz Med Wochenschr 116:1771, 1986.

Voss A, Schmidt K, Hasselbalch H, Junker P: Hypercalcemia in idiopathic myelofibrosis. Am J Hematol 39:231, 1992.

Wang JC, Chen C, Lou L-H, Mora M: Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia. Leukemia 11:1827, 1997.

Dekmezian R, Kantarjian HM, Heating MJ, et al: The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer 59:1739, 1987.

Thiele J, Zankovich R, Steinberg T, et al: Primary (essential) thrombocythemia versus initial hyperplastic stages of agnogenic myeloid metaplasia with thrombocytosis. Acta Haematol 81:192, 1989.

Fortunato A, Mazzone A, Ricevuti G: Myelofibrosis caused by cancer: Presentation of a clinical case with a very difficult diagnosis. Minerva Med 76:1051, 1985.

Yablonski-Peretz T, Sulkes A, Polliack A, et al: Secondary myelofibrosis with metastatic breast cancer simulating agnogenic myeloid metaplasia: Report of a case and review of the literature. Med Pediatr Oncol 13:92, 1985.

Ishimura J, Fukushi M: Scintigraphic evaluation of secondary myelofibrosis associated with prostatic cancer before hormonal therapy. Clin Nucl Med 15:330, 1990.

Smart HE, Canney PA, Kerr DJ: Myelofibrosis associated with metastatic seminoma. Clin Oncol 4:132, 1992.

Takahashi T, Akihama T, Yamaguchi A, et al: Lysozyme secreting tumor: A case of gastric cancer associated with myelofibrosis due to disseminated bone marrow metastasis. Jpn J Med 26:58, 1987.

Rubins JM: The role of myelofibrosis in malignant leukoerythroblastosis. Cancer 51:308, 1983.

Hashim MSK, Kordofani AYA, El Dabi MA: Tuberculosis and myelofibrosis in children. Ann Trop Paediatrics 17:61, 1997.

Sawers AH, Davson J, Braganza J, et al: Systemic mastocytosis, myelofibrosis and portal hypertension. J Clin Pathol 35:617, 1982.

Reisberg IR, Oyakawa S: Mastocytosis with malabsorption, myelofibrosis, and massive ascites. Am J Gastroenterol 82:54, 1987.

Brenner B, Green J, Rosenbaum H, et al: Severe pancytopenia due to marked marrow fibrosis associated with angioimmunoblastic lymphadenopathy. Acta Haematol 74:43, 1985.

Meckenstock G, Wehmeier A, Schaefer HE, et al: Lymphoid myelofibrosis associated with high grade B cell lymphoma of the liver. Leuk Lymph 26:197, 1997.

Vandermolen L, Rice L, Lynch EL: Plasma cell dyscrasia with marrow fibrosis. Am J Med 79:297, 1985.

Humphrey CA, Morris TCM: The intimate relationship of myelofibrosis and myeloma: Effect of therapy. Br J Haematol 73:269, 1989.

Patterson KG, Treleavan JG, Zuiable A: Marrow fibrosis in myeloma: Improvement by alkylating agent therapy. Clin Lab Haematol 18:221, 1988.

Murayama T, Matsui T, Hayaski Y, et al: Plasma cell leukemia with myelofibrosis. Ann Hematol 69:151, 1994.

Schmidt U, Ruwe M, Leder LD: Multiple myeloma with bone marrow biopsy features simulating concomitant chronic idiopathic myelofibrosis. Nouv Rev Franc d’Hematol 37:159, 1995.

Abildgaard N, Bendix-Hanse K, Kristensen JE, et al: Bone marrow fibrosis and disease activity in multiple myeloma monitored by the autoterminal propeptide of procollagen III in serum. Br J Haematol 99:641, 1997.

Nomura S, Ogawa Y, Osawa G, et al: Myelofibrosis secondary to renal osteodystrophy. Nephron 72:683, 1996.

Fontenay-Roupie M, Dupuy E, Berrou E, et al: Increased proliferation of bone-marrow-derived fibroblasts in primary hypertropic osteoarthropy with severe myleofibrosis. Blood 85:3229, 1995.

Jantunen E, Hänninen A, Naukkarinen A, et al: Gray platelet syndrome with splenomegaly and signs of extramedullary hematopoiesis. Am J Hematol 46:218, 1994.

Sadoun A, Lacotte L, Delwail V, et al: Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis. Bone Marrow Transplant 19:741, 1997.

Hatake K, Ohtsuki T, Uwai M, et al: Tretinoin induces bone marrow collagenous fibrosis in acute promyelocytic leukemia. Br J Haematol 93:646, 1996.

Labotka RJ, Morgan RR: Myelofibrosis with neuroblastoma. Med Pediatr Oncol 10:21, 1982.

Karcher DS, Pearson CE, Butler WM, et al: Giant lymph node hyperplasia involving the thymus with associated nephrotic syndrome and myelofibrosis. Am J Clin Pathol 77:100, 1982.

Walka MM, Daümling S, Hadorn HB, et al: Vitamin D dependent rickets type II with myelofibrosis and immune dysfunction. Eur J Pediatr 114:213, 1989.

Al-Eissa YA, Al-Mashhadami SA: Myelofibrosis in severe combined immunodeficiency due to vitamin D deficiency rickets. Acta Haematol 92:160, 1994.

Sartoris DJ, Resnick D: Myelofibrosis arising in treated histiocytosis X. Eur Pediatr 144:200, 1985.

Shah-Reddy I, Subramanian L, Narang S: Myelofibrosis and true histiocytic lymphoma. Tumor 71:509, 1985.

Jennings WH, Li CY, Kiely JM: Concomitant myelofibrosis with agnogenic myeloid metaplasia and malignant lymphoma. Mayo Clin Proc 58:617, 1983.

Epstein RJ, Joshua DE, Kronenberg H: Idiopathic myelofibrosis complicated by lymphoma: Report of two cases. Acta Haematol 73:40, 1985.

Kaufman S, Iuclea S, Reif R: Idiopathic myelofibrosis complicated by chronic lymphatic leukaemia. Clin Lab Haematol 9:81, 1987.

Subramanian VP, Gomez GA, Han T, et al: Coexistence of myeloid metaplasia with myelofibrosis and hairy-cell leukemia. Arch Intern Med 145:164, 1985.

Ji SQ, Zhu M, Wang YZ: Primary macroglobulinemia with myelofibrosis: Report of a case. Chin Med J 100:83, 1987.

Humphrey CA, Morris TCM: The intimate relationship of myelofibrosis and myeloma. Br J Haematol 73:269, 1989.

Meerkin D, Ashkenazi Y, Gottschalk-Sabag S, Hershko C: Plasma cell dyscrasia with myelofibrosis. Cancer 73:625, 1994.

Kakkar N, Vashishta RK, Banerjee AK, et al: Primary pulmonary malignant teratoma with yolk sac element associated with hematologic neoplasia. Respiration 63:52, 1996.

Berner Y, Berrebi A: Myeloproliferative disorders and nonmyelomatous paraprotein: A study of five patients and review of the literature. Isr J Med Sci 22:109, 1986.

Ellis JT, Peterson P: Myelofibrosis in the myeloproliferative disorders. Prog Clin Biol Res 154:19, 1984.

Najean Y, Rain JD, Dresch C, et al: Risk of leukaemia, carcinoma and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera. Leuk Lymph 22(suppl 1):111, 1996.

Najean Y, Rain JD: Treatment of polycythemia vera: use of 32P- alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood 89:2319, 1997.

Randi ML, Barbone E, Fabris F, et al: Post-polycythemia myeloid metaplasia. J Med 25:363, 1994.

Lukowicz DF, Myers TJ, Grasso JA, et al: Sideroblastic anemia terminating in myelofibrosis. Am J Hematol 13:253, 1982.

Hasselbalch H, Berild D: Transition of myelofibrosis to polycythaemia vera. Scand J Haematol 30:161, 1983.

Talarico L, Wolf BC, Kumar A, Weintraub LR: Reversal of bone marrow fibrosis and subsequent development of polycythemia vera in patients with myeloproliferative disorders. Am J Hematol 30:248, 1989.

Palphilon DH, Creamer P, Keeling DH, et al: Restoration of active haemopoiesis in a patient with myelofibrosis and subsequent termination in acute myeloblastic leukaemia: Case report and review of the literature. Eur J Haematol 38:279, 1987.

Besa EC, Nowell PC, Geller NI, Gardner F: Analysis of androgen response of 23 patients with agnogenic myeloid metaplasia. Cancer 49:308, 1982.

Silverstein MN: Treatment of myelofibrosis, in Myelofibrosis: Pathophysiology and Clinical Management, edited by SM Lewis, pp 195–202. Marcel Dekker, New York, 1985.

Chabannon C, Pegourie B, Sotto JJ, Hallard D: Clinical and hematological improvement in a patient receiving danazol therapy for myelofibrosis with myeloid metaplasia. Nouv Rev Fr Hematol 32:165, 1990.

Lévy V, Bourgarit A, Delmer A, et al: Treatment of agnogenic myeloid metaplasia with danazol. Am J Hematol 53:239, 1996.

Makdisi WJ, Cherian R, Vanveldhuizen PJ, et al: Fatal peliosis of the liver and spleen in a patient with agnogenic myeloid metaplasia treated with danazol. Am J Gastroenterol 90:317, 1995.

Ozsoylu S, Ruacan S: High-dose intravenous corticosteroid treatment in childhood idiopathic myelofibrosis. Acta Haematol 75:49, 1986.

Cetingül N, Yener E, Oztop S, et al: Agnogenic myeloid metaplasia in childhood: A report of two cases and efficiency of intravenous high dose methylprednisolone treatment. Acta Pediatr Jpn 36:697, 1994.

Barois G, Liberato LN, Guarnone R: Serum erythropoietin in patients with myeloid metaplasia. Br J Haematol 83:365, 1993.

Rodrigues JN, Martino ML, Muniz R, Prados D: Recombinant human erythropoietin for the treatment of anemia in myelofibrosis with myeloid metaplasia. Am J Hematol 39:435, 1994.

Tefferi A, Silverstein MN: Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 86:893, 1994.

Lofvenberg E, Wahlin A: Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 41:375, 1988.

Lofvenberg E, Wahlin A, Roos G, Ost A: Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 44:33, 1990.

Manoharan A: Management of myelofibrosis with intermittent hydroxyurea. Br J Haematol 71:252, 1991.

Manoharan A, Pitney WR: Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Scand J Haematol 33:453 1984.

Stahl RL, Hoppstein L, Davidson TG: Intraperitoneal chemotherapy with cytosine arabinoside in agnogenic myelofibrosis with myeloid metaplasia and ascites due to peritoneal extramedullary hematopoiesis. Am J Hematol 43:156, 1993.

Carlo-Stella C, Cazzola M, Gasner A, et al: Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitors from patients with myelofibrosis and myeloid metaplasia. Blood 70:1014, 1987.

Sacchi S: The role of a-interferon in essential thrombocythaemia, polycythaema vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Leuk Lymph 19:13, 1995.

Sivera P, Cesano L, Guerrasio A, et al: Clinical and hematological improvement in a patient with idiopathic myelofibrosis and osteosclerosis. Br J Haematol 86:397, 1994.

Greenberger JS, Chaffey JT, Rosenthal DS, et al: Irradiation for control of hypersplenism and painful splenomegaly in myeloid metaplasia. Int J Radiat Oncol Biol Phys 2:1083, 1977.

Parmentier C, Charbord P, Tibi M, et al: Splenic irradiation in myelofibrosis, clinical findings and ferrokinetics. Int J Radiat Oncol Biol Phys 2:1075, 1977.

Wagner H Jr, McKeough PG, Desforges J, et al: Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Cancer 58:1204, 1986.

Jacobs P, Wood L, Robson S: Refractory ascites in the chronic myeloproliferative syndrome. Am J Hematol 37:128, 1991.

Jacobs P, Sellars S: Granulocytic sarcoma preceding leukaemic transformation in myelofibrosis. Postgrad Med J 61:1069, 1985.

Benbassat J, Penchas S, Ligumski M: Splenectomy in patients with agnogenic myeloid metaplasia: An analysis of 321 published cases. Br J Haematol 42:207, 1979.

Brenner B, Nagler A, Tatarsky I, Häsmonai M: Splenectomy in agnogenic myeloid metaplasia and post-polycythemic myeloid metaplasia. Arch Intern Med 148:2501, 1988.

Barosi G, Ambrosetti A, Buratti A, et al: Splenectomy for patients with myelo-fibrosis with myeloid metaplasia. Leukemia 7:200, 1993.

Lafaye F, Rain JD, Clot P, Najean Y: Risks and benefits of splenectomy in myelofibrosis: analysis of 39 cases. Nouv Rev Franc d’Hematol 36:359, 1994.

Towell BL, Levine SP: Massive hepatomegaly following splenectomy for myeloid metaplasia: Case report and review of the literature. Am J Med 82:371, 1987.

DiBella NJ, Silverstein MN, Hoagland HC: Effect of splenectomy on teardrop-shaped erythrocytes in agnogenic myeloid metaplasia. Arch Intern Med 137:380, 1977.

Tefferi A, Silverstein MN, Li CY: 2-chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 99:352, 1997.

Benbassat J, Gilon D, Penchas S: The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. Am J Hematol 33:128, 1990.

Petroianu A, Da Silva RG, Simal CJ, et al: Late postoperative follow-up of patients submitted to subtotal splenectomy. Am Surg 63:735, 1997.

Tefferi A, Barrett SM, Silverstein NM, Nagorney DM: Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia. Am J Hematol 46:325, 1994.

Matzner Y, Polliack A: Bone marrow curettage in myelodysplastic disorders: A stimulus for regeneration in disturbed hematopoiesis. JAMA 246:1926, 1981.

Fruchtman SM: Therapeutic implications of collagen metabolism in myelofibrosis. Prog Clin Biol Res 154:467, 1984.

Petrini M, Cecconi N, Azzara A, et al: 1,25-dihydroxy-vitamin D on the treatment of idiopathic myelofibrosis. Br J Haematol 62:399, 1986.

Richard C, Mazzora F, Iriondo A, et al: The usefulness of 1,25-dihydroxy-vitamin in the treatment of idiopathic myelofibrosis. Br J Haematol 62:399, 1986.

Eugster C, Brun-del-Re GP, Bucher U: The role of 1,25-dihydroxy-vitamin D3 (1,25(OH)2D3) in the treatment of idiopathic myelofibrosis (letter). Br J Haematol 65:381, 1987.

Arlet P, Nicodeme R, Adoue D, et al: Clinical evidence for 1-dihydroxycholecalciferol action in myelofibrosis (letter). Lancet 1:1013 1984.

Rewald E. de las Mercedes Francischetti: Combining interferon-alpha2b (IFN) and intravenous immunoglobulins IgG, IgM and IgA (IVIG) in rapid progressive myelofibrosis (MF) with Trisomy 1 (letter). Am J Hematol 54:340, 1997.

Pietrasanta D, Clavio M, Vallebella E, et al: Long-lasting effect of cyclosporin-A on anemia associated with idiopathic myelofibrosis. Haematologica 82:458, 1997.

Singhal S, Powles R, Treleaven J, et al: Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant 16:743, 1995.

Guardiola P, Anderson JE, Bandini G, et al: Allogeneic bone marrow transplantation for agnogeneic myeloid metaplasia. Blood 93:2831, 1999.

Przepiorka D, Giralt S, Khour I, et al: Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 7:24, 1998.

Visini G, Finelli C, Castelli U, et al: Myelofibrosis with myeloid metaplasia: Clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 75:4, 1990.

Rozman C, Giralt M, Feliu E, et al: Life expectancy of patients with chronic non-leukemic myeloproliferative disorders. Cancer 67:2658, 1991.

Silverstein MN, Brown AL, Linman JW: Idiopathic myeloid metaplasia, its evolution into acute leukemia. Arch Intern Med 132:709, 1973.

Marcus RE, Hibbin JA, Matutes E, et al: Megakaryoblastic transformation of myelofibrosis with expression of the c-sis oncogene. Am J Haematol 36:186, 1986.

Hernandez JM, SanMiguel JF, Gonzalez M, et al: Development of acute leukaemia after idiopathic myelofibrosis. J Clin Pathol 45:427, 1992.

Chan ACL, Kwong Y-L, Lam CCK: Granulocytic sarcoma of megakaryoblastic differentiation complicating chronic idiopathic myelofibrosis. Hem Pathol 27:417, 1996.

Polliack A, Prokocimer M, Matzner Y, et al: Lymphoblastic leukemic transformation (lymphoblastic crisis) in myelofibrosis and myeloid metaplasia. Am J Hematol 9:211, 1980.

Yinon A, Kopolovic J, Dollberg L, Hershko C: Evolution of malignant lymphoma in agnogenic myeloid metaplasia. Oncology 45:373, 1988.

Barosi G, Ambrosetti A, Centra A: Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood 91:3630, 1998.

Shreiner DP: Spontaneous hematologic remission in agnogenic myeloid metaplasia. Am J Med 60:1014, 1976.

Rani MV, Shreiner DP: Spontaneous “remission” of agnogenic myeloid metaplasia and termination in acute myeloid leukemia. Arch Intern Med 141:1481, 1981.

Mesa R, Silverstein MN, Jacobsen SJ, et al: Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmstead County Study, 1976–1995. Am J Hematol 61:10, 1999.

Tefferi A: Myelofibrosis with myeloid metaplasia. New Eng J Med 342:1255, 2000.

Tefferi A, Mesa RA, Nagorney DM, et al: Splenectomy in myelofibrosis with myeloid metaplasia. Blood 95:2226, 2000.
Copyright © 2001 McGraw-Hill
Ernest Beutler, Marshall A. Lichtman, Barry S. Coller, Thomas J. Kipps, and Uri Seligsohn
Williams Hematology


  1. […] FDA warning about severe bone pain and osteoporosis drugs like FosamaxCHAPTER 95 IDIOPATHIC MYELOFIBROSIS (AGNOGENIC MYELOID METAPLASIA) […]

  2. […] CRAVE Portland & American Cancer Society “Making Strides Against Breast Cancer” • CRAVE Portland • Connect. Inspire. Succeed.Pink Gloves in Portland for Breast Cancer AwarenessCHAPTER 95 IDIOPATHIC MYELOFIBROSIS (AGNOGENIC MYELOID METAPLASIA) […]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: